Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Organon & Co.

Get SEC filing alerts via email and in your feed for Organon & Co.

OGN

Organon & Co.

About Organon & Co.

Organon & Co. is a global healthcare company specializing in women’s health, biosimilars, and established brands. It develops and markets prescription therapies and medical devices across therapeutic areas like contraception, fertility, oncology, immunology, and cardiovascular health. Serving patients worldwide, it leverages a diversified product portfolio, manufacturing capabilities, and strategic collaborations to deliver innovative, cost-effective solutions in competitive markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Organon & Co.

1
1
Organon & Co. Organon & Co. Reports $1.46 Billion Revenue, Net Income Rises to $146 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Organon & Co. Organon Reports $6.2 Billion Revenue for Fiscal Year 2025, Faces Decline in Key Product Sales

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Organon & Co. Organon & Co. Reports Q3 2025 Financial Results with $1.602 Billion Revenue

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Organon & Co. Organon & Co. Reports Q2 2025 Revenue of $1.594 Billion, Net Income Declines

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Organon & Co. Organon & Co. Reports 7% Revenue Decline and Strategic Acquisitions in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Organon & Co. Organon Reports $6.4 Billion Revenue with 2% Growth, Net Income Decline in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Organon & Co. Organon & Co. Reports 4% Revenue Growth, Net Income Surge in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments